logo
King Charles' Cancer Is Incurable, Bombshell Report Suggests

King Charles' Cancer Is Incurable, Bombshell Report Suggests

Yahoo7 hours ago

King Charles' will die 'with' but not 'of' cancer, a bombshell report claimed Saturday.
The report essentially confirms long-standing rumors that the king's cancer is considered manageable but ultimately incurable, which is the case for many older individuals afflicted by the disease.
Charles is 76.
The report will be unwelcome in the palace, as it will reignite speculation that the king's health is in a delicate state, rumors that were brought to fever pitch when Prince Harry said in a recent BBC interview that he didn't know how long his father had left to live.
Charles' aides have consistently briefed reporters that he is, broadly speaking, winning his battle against cancer and the king himself recently said he was on 'the other side' of the health crisis.
The king is back to essentially running a full diary after being diagnosed with cancer last year, albeit with some modifications.
The report, by the respected royal writer and associate editor of the U.K. Daily Telegraph, Camilla Tominey, also claimed that Charles will never move into Buckingham Palace due to his health struggles.
'The talk now is that he may die 'with' cancer, but not 'of' cancer following a rigorous treatment program,' she wrote.
A spokesperson for the king declined to comment.
Tominey who was the first to break the news about Prince Harry and Meghan dating and also about the latter's row with Kate Middleton.
The report added that planning for Charles' 80th birthday in 2028, while 'very tentative,' is going ahead.
Tominey also claimed that Charles and Harry could be publicly reunited at the Invictus Games, in Birmingham in 2027, with palace aides quietly investigating whether the event could provide a suitable backdrop for a long-awaited reconciliation.
It is understood officials hope any reconciliation would include Prince Archie and Princess Lilibet. The king last saw the children in 2022. Harry has said he can't bring his family safely to the U.K. and hinted some powerful palace figures want him dead.
Intriguingly, Tominey suggests that a reconciliation might be considered because of the negative impact the narrative of estrangement is having on the king's reputation.
She writes: 'There is an awareness that the impasse cannot continue forever, not least if it starts to reflect badly on the king.'
Prince Harry said, in a bitter interview with the BBC following a comprehensive legal defeat on his security arrangements, that he does not know how long his cancer-hit father has left to live because the king won't speak to him.
Harry also said he won't bring his family to the U.K., blamed his father for his security being reduced after leaving the royal family, and said he had 'forgiven' those family members who had hurt him.
He added: 'Some members of my family will never forgive me for writing a book but I would love reconciliation with my family.'
Appearing emotional, the prince added: 'I don't know how much longer my father has. He won't speak to me because of this security stuff.'
'There is a lot of control and ability in my father's hands. Ultimately, this whole thing could be resolved through him,' Harry said.
​'There's no point in continuing to fight anymore. As I said, life is precious. I don't know how much longer my father has. He won't speak to me because of this security stuff, but it would be nice to reconcile.'

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Coherus BioSciences, Inc. (CHRS): A Bull Case Theory
Coherus BioSciences, Inc. (CHRS): A Bull Case Theory

Yahoo

time23 minutes ago

  • Yahoo

Coherus BioSciences, Inc. (CHRS): A Bull Case Theory

We came across a bullish thesis on Coherus BioSciences, Inc. (CHRS) on Steve Wagner's Substack. In this article, we will summarize the bulls' thesis on CHRS. Coherus BioSciences, Inc. (CHRS)'s share was trading at $0.77 as of 30th May. CHRS's trailing P/E was 1.77 according to Yahoo Finance. Scientist in a lab working on a research project, focusing on biotechnology and healthcare advancements. Coherus BioSciences (CHRS), long overlooked by Wall Street, is taking a bold step into innovative oncology by partnering with UK-based STORM Therapeutics to test a novel cancer treatment strategy. The collaboration brings together Coherus's immunotherapy toripalimab (LOQTORZI) and STORM's first-in-class RNA-modifying enzyme inhibitor STC-15 in a Phase 1b/2 clinical trial. This unexpected pairing represents a fresh approach to immuno-oncology, targeting cancer through dual mechanisms that could produce synergistic effects. Toripalimab, already approved in the U.S. for nasopharyngeal carcinoma and under review for broader indications, offers proven checkpoint inhibition, while STC-15 introduces a cutting-edge method of disrupting RNA methylation processes linked to tumor growth and immune evasion. If this combo demonstrates efficacy, it could represent a completely new class of cancer therapy and place Coherus at the forefront of next-generation immuno-oncology innovation. Importantly, this partnership shows strategic vision from CHRS's management as they seek to differentiate the company beyond biosimilars and move deeper into proprietary immunotherapy. With the trial still in early stages and little market attention so far, the risk/reward profile for investors is potentially skewed to the upside. Should the data prove positive, the impact could be significant for both companies, especially for CHRS as it repositions itself as a serious player in oncology innovation. This under-the-radar development deserves close monitoring, as it could catalyze a major reevaluation of Coherus's valuation and growth trajectory. Previously, we have covered CHRS in March 2025 wherein we summarized a by the same author. Coherus BioSciences (CHRS) posted a strong turnaround in 2024 with $267M in revenue and $28.5M net income, driven by Loqtorzi's growth and the planned $250M Udenyca divestiture. The company pivoted fully to oncology, trimmed costs, and advanced its pipeline, yet management expressed frustration over the stock's undervaluation, hinting at potential M&A. Since our last coverage, the stock is down 38% as of 30th May. We don't trust CHRS' management as the stock lost more than 95% of its value in recent years and is still losing a ton of money. The market agrees with us and thinks this stock is going to go bankrupt. We believe CHRS should stop wasting shareholder's money, sell valuable assets, and liquidate the company. We don't think that's a likely outcome. Coherus BioSciences, Inc. (CHRS) is not on our list of the 30 Most Popular Stocks Among Hedge Funds. As per our database, 10 hedge fund portfolios held CHRS at the end of the first quarter which was 10 in the previous quarter. While we acknowledge the potential of CHRS as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the best short-term AI stock. READ NEXT: 8 Best Wide Moat Stocks to Buy Now and 30 Most Important AI Stocks According to BlackRock. Disclosure: None. This article was originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Botulism cases from Botox injections linked to Milton spa, health officials say
Botulism cases from Botox injections linked to Milton spa, health officials say

CBS News

timean hour ago

  • CBS News

Botulism cases from Botox injections linked to Milton spa, health officials say

The Massachusetts Department of Public Health (DPH) has linked a Milton spa to a string of botulism cases from Botox injections. Ten people are suspected to have iatrogenic botulism, a rare but serious illness, after receiving a procedure at Rodrigo Beauty on Granite Avenue. Health officials advise that anyone who received Botox injections between May 1 and June 4 should contact their nearby health department or DPH. Iatrogenic botulism can happen when Botox spreads beyond where it was injected. Symptoms of iatrogenic botulism include blurred or double vision, slurred speech, breathing difficulties, drooping eyelids, and difficulty swallowing. Some more serious cases may experience progressive muscle weakness. If you experience any of these symptoms, the DPH recommends visiting the nearest emergency room. "Early recognition and treatment can significantly improve outcomes," the DPH said in a statement. The DPH asks that anyone contact them with questions or concerns at 617-983-6800. What is Botox? Cosmetic botulinum toxin, commonly referred to as Botox injections, is a "purified substance derived from bacteria," according to the American Society of Plastic Surgeons. It blocks the nerve signal to the muscle, which prevents the muscle from moving. It is commonly used to prevent wrinkles in the face. The Massachusetts DPH emphasizes that trained professionals should inject Botox and that the technique, use of non-FDA-approved products, and improper dosing increase the risk of botulism. Massachusetts spa owner arrested A Stoughton spa owner, with locations in Easton and Randolph, was arrested in November of 2024 for allegedly using illegal counterfeit Botox and filler injections. Thirty-eight-year-old Rebecca Fadanello allegedly performed thousands of injections using imported Botox, Sculptra, and Juvederm from China and Brazil. She purchased the products from Alibaba, a Chinese company that claims to sell products in bulk. She was charged with one count of illegally importing merchandise contrary to law, one count of selling or dispensing a counterfeit drug, and one count of selling or dispensing a counterfeit device.

Dawn French apologises for 'clumsy tone' in Gaza clip
Dawn French apologises for 'clumsy tone' in Gaza clip

Yahoo

time2 hours ago

  • Yahoo

Dawn French apologises for 'clumsy tone' in Gaza clip

Dawn French has posted a public apology after posting a video about the war in Gaza, and removed the item from her social media. The 40-second video posted earlier this week showed the star of BBC sitcom The Vicar of Dibley share her views on the conflict, saying "Complicated, no, but nuanced. But bottom line is no." Switching into a high-pitched voice, she continued: "Yeah, but you know they did a bad thing to us, yeah but no. But we want that land... and we have history... No. Those people aren't really even people, are they really? No." Following a backlash with people complaining she was mocking the 7 October attack that ignited the war, French removed the video on Saturday and said she never meant to "mock, or dismiss, or diminish the horror" of the event. "I hope you will understand my intention was not to offend, but I clearly have. For which I am sorry and I have removed the video." French said that she had posted a video in the style that she has been using for social media "in an effort to convey an important point", although she added that she had "clumsily used a mocking tone". "My intention was never to mock, or dismiss, or diminish the horror of what happened on 7 October 2023 and what continues to unfold from that brutal unthinkable, unforgivable, savage attack." She said her intention had been "to point the finger of shame at the behaviour of the cruel leaders on all sides of this atrocious war".

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store